EUROPE DRUG DISCOVERY MARKET FORECAST 2019-2027

EUROPE DRUG DISCOVERY MARKET FORECAST 2019-2027
Europe Drug Discovery Market by Technology (High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics and Pharmacogenetics, Combinatorial, Chemistry, Nanotechnology, Spectroscopy, Metabolomics, Other Technologies) by Drug Type (Small Molecule Drug, Biologic Drug) by Service (Drug Metabolism and Pharmacokinetics, (Dmpk) Services, Chemical Services, Biological Services, Other Pharmaceutical Services) by End User (Research Institutes, Pharmaceutical Companies, Contract Research Organizations (Cros), Other End User) by Geography.
The European drug discovery market contributed revenue of $XX million in 2018 and is estimated to generate $XX million by 2027. According to Inkwood Research, the market will proceed to grow with an expected 8.22% CAGR over the forecast period of 2019-2027. The increasing healthcare spending in European countries is influencing the drug discovery market in the region.
Growing prevalence of cardiovascular diseases, along with favourable government policies, are driving the growth of the drug discovery market in the region. Europe has been adopting the latest healthcare system to provide better care and treatment for patients. However, the delay in product launches due to drug regulations and norms is hindering the drug discovery market growth.
The Europe drug discovery market analysis encompasses countries such as Germany, Spain, France, Italy, the United Kingdom, and Rest of Europe regional segment, which includes remaining European countries. German drug discovery market is predicted to exhibit mounting growth owing to a better healthcare system. The country also has the presence of large biotechnology and pharmaceuticals companies that develops innovative technology and products, thereby boosting the drug discovery market.
Many prominent players operate in the drug discovery market; one of the leading players in the market is AstraZeneca PLC, which is a UK-based biopharmaceutical company. The company focuses on the development, discovery, and commercialization of prescription medicines that are used in the treatment of several diseases. It operates in numerous countries and has a wide range of products portfolio. Other companies include Bayer AG and Boehringer Ingelheim.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP-DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- HIGH PREVALENCE RATES OF MAJOR HEALTH DISORDERS
- IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS
- BIOINFORMATICS IS THE WIDELY USED DRUG DISCOVERY TECHNOLOGY
- SMALL MOLECULE DRUG TYPE CONSTITUTES THE HIGHEST MARKET SHARE
- CONTRACT RESEARCH ORGANIZATIONS (CROS) ARE THE FASTEST-GROWING END USER
- MARKET DYNAMICS
- MARKET SCOPE & DEFINITION
- MARKET DRIVERS
- AGING POPULATION
- BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
- GROWING HEALTHCARE EXPENDITURE
- TECHNOLOGICAL ADVANCEMENT
- MARKET RESTRAINTS
- DELAY IN PRODUCT LAUNCHES
- POOR ACCESS TO HEALTHCARE SERVICES IN DEVELOPING MARKETS
- SHIFT FROM BRANDED TO GENERIC DRUGS
- MARKET OPPORTUNITIES
- EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
- INCREASING DEMAND FOR SPECIALTY MEDICINES
- RISING INVESTMENT BY PHARMACEUTICAL COMPANIES IN IMPROVING BIG-DATA ANALYTICAL CAPABILITIES
- MARKET CHALLENGES
- COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
- STRINGENT GOVERNMENT REGULATIONS
- MARKET BY TECHNOLOGY
- HIGH THROUGHPUT SCREENING
- BIOCHIPS
- BIOINFORMATICS
- PHARMACOGENOMICS AND PHARMACOGENETICS
- COMBINATORIAL CHEMISTRY
- NANOTECHNOLOGY
- SPECTROSCOPY
- METABOLOMICS
- OTHER TECHNOLOGIES
- MARKET BY DRUG TYPE
- SMALL MOLECULE DRUG
- BIOLOGIC DRUG
- MARKET BY SERVICE
- DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
- CHEMICAL SERVICES
- BIOLOGICAL SERVICES
- OTHER PHARMACEUTICAL SERVICES
- MARKET BY END USER
- RESEARCH INSTITUTES
- PHARMACEUTICAL COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS (CROS)
- OTHER END USER
- KEY ANALYTICS
- PORTER’S FIVE FORCES MODEL
- THREATS OF NEW ENTRANTS
- THREAT OF SUBSTITUTE PRODUCTS
- BARGAINING POWER OF BUYERS
- BARGAINING POWER OF SUPPLIERS
- COMPETITIVE RIVALRY
- VALUE CHAIN ANALYSIS
- PESTLE ANALYSIS
- REGULATORY FRAMEWORK
- OPPORTUNITY MATRIX
- PORTER’S FIVE FORCES MODEL
- GEOGRAPHICAL ANALYSIS
- EUROPE
- THE UNITED KINGDOM
- FRANCE
- GERMANY
- SPAIN
- ITALY
- REST OF EUROPE
- EUROPE
- COMPANY PROFILES
- 3M COMPANY
- ANTARES PHARMA
- ASTRAZENECA PLC
- BAYER AG
- BECTON, DICKINSON & COMPANY (BD)
- BOEHRINGER INGELHEIM
- ELI LILY
- HOFFMANN-LA ROCHE LTD
- GLAXOSMITHKLINE LLC
- JOHNSON AND JOHNSON
- MERCK & CO. INC.
- NOVARTIS
- PFIZER, INC.
- SANOFI
LIST OF TABLES
TABLE 1 EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
TABLE 2 EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2019-2027 ($ MILLION)
TABLE 3 EUROPE HIGH THROUGHPUT SCREENING MARKET, 2019-2027 ($ MILLION)
TABLE 4 EUROPE BIOCHIPS MARKET, 2019-2027 ($ MILLION)
TABLE 5 EUROPE BIOINFORMATICS MARKET, 2019-2027 ($ MILLION)
TABLE 6 EUROPE PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, 2019-2027 ($ MILLION)
TABLE 7 EUROPE COMBINATORIAL CHEMISTRY MARKET, 2019-2027 ($ MILLION)
TABLE 8 EUROPE NANOTECHNOLOGY MARKET, 2019-2027 ($ MILLION)
TABLE 9 EUROPE SPECTROSCOPY MARKET, 2019-2027 ($ MILLION)
TABLE 10 EUROPE METABOLOMICS MARKET, 2019-2027 ($ MILLION)
TABLE 11 EUROPE OTHER TECHNOLOGIES MARKET, 2019-2027 ($ MILLION)
TABLE 12 EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2027 ($ MILLION)
TABLE 13 EUROPE SMALL MOLECULE DRUG MARKET, 2019-2027 ($ MILLION)
TABLE 14 EUROPE BIOLOGIC DRUG MARKET, 2019-2027 ($ MILLION)
TABLE 15 EUROPE DRUG DISCOVERY MARKET, BY SERVICE, 2019-2027 ($ MILLION)
TABLE 16 EUROPE DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET, 2019-2027 ($ MILLION)
TABLE 17 EUROPE CHEMICAL SERVICES MARKET, 2019-2027 ($ MILLION)
TABLE 18 EUROPE BIOLOGICAL SERVICES MARKET, 2019-2027 ($ MILLION)
TABLE 19 EUROPE OTHER PHARMACEUTICAL SERVICES MARKET, 2019-2027 ($ MILLION)
TABLE 20 EUROPE DRUG DISCOVERY MARKET, BY END USER, 2019-2027 ($ MILLION)
TABLE 21 EUROPE RESEARCH INSTITUTES MARKET, 2019-2027 ($ MILLION)
TABLE 22 EUROPE PHARMACEUTICAL COMPANIES MARKET, 2019-2027 ($ MILLION)
TABLE 23 EUROPE CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET, 2019-2027 ($ MILLION)
TABLE 24 EUROPE OTHER END USER MARKET, 2019-2027 ($ MILLION)
TABLE 25 EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
LIST OF FIGURES
FIGURE 1 EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
FIGURE 2 EUROPE DRUG DISCOVERY MARKET SHARE BY TECHNOLOGY 2018 & 2027 (%)
FIGURE 3 EUROPE DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 ($ MILLION)
FIGURE 4 EUROPE DRUG DISCOVERY MARKET, BY BIOCHIPS, 2019-2027 ($ MILLION)
FIGURE 5 EUROPE DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2019-2027 ($ MILLION)
FIGURE 6 EUROPE DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2027 ($ MILLION)
FIGURE 7 EUROPE DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2019-2027 ($ MILLION)
FIGURE 8 EUROPE DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2019-2027 ($ MILLION)
FIGURE 9 EUROPE DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2019-2027 ($ MILLION)
FIGURE 10 EUROPE DRUG DISCOVERY MARKET, BY METABOLOMICS, 2019-2027 ($ MILLION)
FIGURE 11 EUROPE DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2019-2027 ($ MILLION)
FIGURE 12 EUROPE DRUG DISCOVERY MARKET SHARE BY DRUG TYPE 2018 & 2027 (%)
FIGURE 13 EUROPE DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2019-2027 ($ MILLION)
FIGURE 14 EUROPE DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2019-2027 ($ MILLION)
FIGURE 15 EUROPE DRUG DISCOVERY MARKET SHARE, BY SERVICE, 2018 & 2027 (%)
FIGURE 16 EUROPE DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES, 2019-2027 ($ MILLION)
FIGURE 17 EUROPE DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2019-2027 ($ MILLION)
FIGURE 18 EUROPE DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2019-2027 ($ MILLION)
FIGURE 19 EUROPE DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2019-2027 ($ MILLION)
FIGURE 20 EUROPE DRUG DISCOVERY MARKET SHARE, BY END USER, 2018 & 2027 (%)
FIGURE 21 EUROPE DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2019-2027 ($ MILLION)
FIGURE 22 EUROPE DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2019-2027 ($ MILLION)
FIGURE 23 EUROPE DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2027 ($ MILLION)
FIGURE 24 EUROPE DRUG DISCOVERY MARKET, BY OTHER END USER, 2019-2027 ($ MILLION)
FIGURE 25 PORTER’S FIVE FORCE MODEL
FIGURE 26 EUROPE DRUG DISCOVERY MARKET, REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 27 THE UNITED KINGDOM DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
FIGURE 28 FRANCE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
FIGURE 29 GERMANY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
FIGURE 30 SPAIN DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
FIGURE 31 ITALY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
FIGURE 32 REST OF EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
- GEOGRAPHICAL ANALYSIS
- EUROPE
- THE UNITED KINGDOM
- FRANCE
- GERMANY
- SPAIN
- ITALY
- REST OF EUROPE
- EUROPE
- MARKET BY TECHNOLOGY
- HIGH THROUGHPUT SCREENING
- BIOCHIPS
- BIOINFORMATICS
- PHARMACOGENOMICS AND PHARMACOGENETICS
- COMBINATORIAL CHEMISTRY
- NANOTECHNOLOGY
- SPECTROSCOPY
- METABOLOMICS
- OTHER TECHNOLOGIES
- MARKET BY DRUG TYPE
- SMALL MOLECULE DRUG
- BIOLOGIC DRUG
- MARKET BY SERVICE
- DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
- CHEMICAL SERVICES
- BIOLOGICAL SERVICES
- OTHER PHARMACEUTICAL SERVICES
- MARKET BY END USER
- RESEARCH INSTITUTES
- PHARMACEUTICAL COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS (CROS)
- OTHER END USER
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.